revise and submit the protocol to FDA for a Special Protocol
Assessment prior to initiating the registration trial.
- OncoGenex completed patient enrollment in its Phase 1 clinical trial
evaluating the safety of SN2310 in patients with advanced cancer.
Conference Call on Monday, November 10, 2008 at 4:30 p.m. Eastern Time
OncoGenex management will host a conference call on Monday, November 10, 2008, at 4:30 p.m. Eastern Time to provide a business and product update and discuss the third quarter results. To access the webcast, log on to the Investor Relations page of the OncoGenex Web site at http://www.oncogenex.com. Alternatively, you may access the live conference call by dialing 877-548-7903 (U.S. & Canada) or 719-325-4917 (International). A webcast replay will be available approximately two hours after the call and will be archived on http://www.oncogenex.com for 90 days.
About OncoGenex Pharmaceuticals
OncoGenex Pharmaceuticals is a biopharmaceutical company committed to
the development and commercialization of new therapies that address unmet
needs in the treatment of cancer. OncoGenex has a deep oncology pipeline,
with each product candidate having a distinct mechanism of action and
representing a unique opportunity for cancer drug development. OGX-011, the
lead candidate currently completing five Phase 2 clinical studies in
prostate, lung and breast cancers, is designed to inhibit the production of
a specific protein associated with treatment resistance; OGX-427 is in
Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1
clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical
development. More information is available at http://www.oncogenex.com
|SOURCE OncoGenex Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved